Literature DB >> 21221960

Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey.

Masaaki Watanabe, Masato Homma, Kenji Momo, Yasushi Okoshi, Tetsuro Wada, Akira Hara, Shigeru Chiba, Yukinao Kohda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21221960     DOI： 10.1007/s00228-010-0968-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  7 in total

1.  Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.

Authors:  Bojan Lalovic; Evan Kharasch; Christine Hoffer; Linda Risler; Lee-Yuan Liu-Chen; Danny D Shen
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

3.  Plasma concentrations of oral oxycodone are greatly increased in the elderly.

Authors:  A Liukas; K Kuusniemi; R Aantaa; P Virolainen; M Neuvonen; P J Neuvonen; K T Olkkola
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

4.  Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study.

Authors:  P Mucci-LoRusso; B S Berman; P T Silberstein; M L Citron; L Bressler; S M Weinstein; R F Kaiko; B J Buckley; R F Reder
Journal:  Eur J Pain       Date:  1998       Impact factor: 3.931

5.  Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer.

Authors:  K P Leow; M T Smith; B Williams; T Cramond
Journal:  Clin Pharmacol Ther       Date:  1992-11       Impact factor: 6.875

6.  Voriconazole drastically increases exposure to oral oxycodone.

Authors:  Nora M Hagelberg; Tuija H Nieminen; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2008-10-03       Impact factor: 2.953

7.  Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.

Authors:  Teijo I Saari; Juha Grönlund; Nora M Hagelberg; Mikko Neuvonen; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2010-04       Impact factor: 2.953
  7 in total
  4 in total

1.  Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects.

Authors:  Nora M Hagelberg; Tuija H Nieminen; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2011-01-11       Impact factor: 2.953

2.  Respiratory depression related to multiple drug-drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone.

Authors:  Bruno Charpiat; Michel Tod; Benjamin Darnis; Guillaume Boulay; Marie-Claude Gagnieu; Jean-Yves Mabrut
Journal:  Eur J Clin Pharmacol       Date:  2017-03-09       Impact factor: 2.953

Review 3.  Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.

Authors:  Karin C Söderberg Löfdal; Marine L Andersson; Lars L Gustafsson
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 4.  Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review.

Authors:  Aleksandra Kotlinska-Lemieszek; Pål Klepstad; Dagny Faksvåg Haugen
Journal:  Drug Des Devel Ther       Date:  2015-09-16       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.